Clovis Oncology shares shot up more than 26 percent Tuesday after the FDA accepted the company's new drug application.
Shares of Clovis surge on positive FDA news, CNBC's Melissa Lee reports.
How is the EpiPen outrage impacting families, parents and children who need these products as protection against fatal allergy attacks? CNBC's Kate Kelly and Sue Herera discuss how its affecting their own children.
Tim Chiang, BTIG managing director, shares his take on Mylan, admid the EpiPen price outrage.
Alex Tarrant, assistant editor at Dealreporter Europe, Mergermarket Group, shares his views on the deal between Pfizer and Medivation.
Aug 22- Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. Medivation shares jumped nearly 20 percent to close at $80.42, just shy of the offer price of $81.50 per share.
Medivation Inc., up $13.26 to $80.42. The cancer drugmaker agreed to be bought by Pfizer for $13.5 billion, or $81.50 a share. Marathon Oil Corp., down $1.16 to $15.64.
TORONTO, Aug 22- Canada's main stock index rose on Monday as Alimentation Couche-Tard Inc jumped after the convenience store operator bought a U.S. chain in an expansion move and drugmaker Valeant Pharmaceuticals rose after it hired a new chief financial officer. Couche-Tard jumped 7.5 percent to C $66.78 after the company said it would buy U.S. chain CST...
NEW YORK— Stocks closed slightly lower in quiet trading Monday after drifting most of the day between gains and losses. Energy companies fell along with the price of oil while biotechnology and drug companies rose after Pfizer announced it was buying a cancer drug maker. The Dow Jones industrial average shed 23.15 points, or 0.1 percent, to 18,529.42.
Aug 22- Medivation's $14 billion sale to U.S. drug giant Pfizer Inc for a hefty premium, the largest U.S. biotechnology acquisition so far this year, had investors on Monday speculating about more dealmaking in the sector. Incyte and Seattle Genetics, which have respective market capitalizations of $15.4 billion and $6.7 billion, focus on innovative cancer...
Iowa Senator Chuck Grassley sends a letter to Mylan CEO Heather Bresch about EpiPen pricing. CNBC's Meg Tirrell reports.
As biotech stocks rally, Chad Morganlander, Stifel Nicolaus, and Jonathan Krinsky, MKM Partners, share their take on the biotech sector.
Aug 22- Pfizer Inc, beating out numerous other bidders, said it would buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. Medivation shares were up 20 percent at $80.43 in afternoon trading, just shy of the offer price of $81.50 per share.
CNBC's Meg Tirrell discusses the latest healthcare mergers and acquisitions.
Medivation shares were up 20 percent at $80.43 in midday trading, just shy of the offer price of $81.50 per share. The offer is at a substantial premium to Sanofi SA's initial offer to buy Medivation for $52.50 in April that pushed the San Francisco- based company to put itself up for sale. Pfizer has since bought Anacor Pharmaceuticals Inc in a $5.2 billion deal to...
Halliburton and Transocean each lost 4 percent Monday. The Nasdaq composite notched a small gain as biotech companies rose following the acquisition of pharmaceutical company Medivation, but other major indexes edged lower. Stocks are moving slightly lower in midday trading on Wall Street, led by declines in energy stocks as the price of crude oil sinks.
The embattled drug maker calling on the former Zoetis executive to replace Robert Rosiello.
The acquisition will give Pfizer access to Medivation's successful cancer treatments under development.
Dr. Scott Gottlieb, American Enterprise Institute, talks about the need for Congress to expedite funding for Zika research as scientist attempt to find a vaccine against the virus.
Pfizer will pay about $14 billion to buy cancer drug developer Medivation in a cash deal aimed at fortifying its hold in one of the hottest and most lucrative areas of medicine. The New York drugmaker said Monday that the acquisition will stock its product portfolio with leading treatments for the most common cancers in men and women by adding Medivation's...